Int. J. Mol. Sci., Volume 22, Issue 2 (January-2 2021) – 509 articles
Cover Story (view full-size image): Tyrosine kinase activity of epidermal growth factor receptor (EGFR) plays a critical role in cell proliferation, regeneration, tumorigenesis, and anticancer drug resistance. Non-small-cell lung cancer patients responding to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) with survival benefits had somatic EGFR mutations. EGFR-TKI-related adverse events are tolerable and manageable; serious events like lung injury (interstitial lung disease causes 58% of EGFR-TKI treatment-related deaths) seldom occur. Risk factors like smoking, interstitial pneumonia, and chronic obstructive pulmonary disease are indicators of chronic inflammation in the pulmonary tissues. Relationship between inflammatory cytokines and EGFR-TKIs, perhaps contribute to the occurrence or progression of EGFR-TKI-induced lung injury. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.